Truecaller completes the acquisition of TextPlus Inc.
Truecaller announced on
About TextPlus
Founded in 2009, TextPlus is a US-based communications technology company providing cloud-based voice, messaging and connectivity services through its proprietary mobile platform. TextPlus has built a large and diversified user base of approximately 1.5 million monthly active users serving consumers seeking affordable, app-based communication solutions. TextPlus is headquartered in
Advisors
DNB Carnegie Investment Bank AB acted as financial advisor, Squire Patton Boggs (US) LLP as legal advisor, and KPMG as financial and tax due diligence advisor in relation to the Acquisition for Truecaller.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP acted as legal advisors to TextPlus and The Raine Group served as exclusive financial advisor to TextPlus.
For more information, please contact:
+46 705 290800
[email protected]
About Truecaller:
Truecaller (TRUE B) is the leading global platform for safe and trusted communication. Fraud and unwanted communication are endemic to digital economies. especially in emerging markets. We are on a mission to build trust in communication. Truecaller is an essential part of everyday communication for more than 500 million active users. Truecaller is listed on Nasdaq Stockholm since 8 October 2021. For more information please visit corporate.truecaller.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
|
Textplus_eng_260911 |
View original content:https://www.prnewswire.com/news-releases/truecaller-completes-the-acquisition-of-textplus-inc-302876181.html
SOURCE Truecaller AB
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nvidia’s Huang says cybersecurity will be next major AI use case
- TORM plc capital increase in connection with exercise of Restricted Share Units as part of TORM's incentive program
- The U.S. FDA grants orphan drug designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for treatment of endogenous Cushing's syndrome
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share